A phase 1b study on the safety of Wharton’s jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease
MSCTC-0010 demonstrated an excellent safety profile with no grade ≥3 TRAEs and no ectopic tissue formation. Promising early efficacy-including 71% day 28 OR and 42% day 90 CR in a population with historically poor outcomes-supports further investigation. A randomized multicenter phase 2 trial combining or sequencing MSCTC-0010 with ruxolitinib is warranted to clarify its therapeutic contribution in HR/SR aGVHD.
Authors
- Scott J. Weir (ORCID: https://orcid.org/0000-0002-8020-434X)
- Tyce Bruns
- William Wesson (ORCID: https://orcid.org/0000-0002-9534-0512)
- Rupal P. Soder (ORCID: https://orcid.org/0000-0002-4567-6843)
- Ramesh Balusu (ORCID: https://orcid.org/0000-0003-1441-6528)
- Haitham Abdelhakim
- Joseph P. McGuirk (ORCID: https://orcid.org/0000-0002-0539-4796)
- Milind A. Phadnis (ORCID: https://orcid.org/0000-0001-6472-9325)
- Sunil Abhyankar (ORCID: https://orcid.org/0000-0002-8578-1226)
- Jianzheng Wu
Institutions
- University of Kansas (US)
- The University of Kansas Health System (US)
- University of Kansas Medical Center (US)
Publication Details
- Journal
- Cytotherapy
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1016/j.jcyt.2025.102012
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Georgia Clinical and Translational Science Alliance
- Cancer Center, University of Kansas
- National Cancer Institute
- National Center for Advancing Translational Sciences